Crestor

Strong Tagrisso soothes AZ as US sales plummet

Sales decline 34% in the US due to low-cost copies of Crestor. ... That impact was felt particularly strongly in the US, where sales declined 34% to $1.49bn thanks largely to the launch of low-cost copies of cholesterol drug Crestor (rosuvastatin) in

2017 set to be a "defining year" for AZ

The last AZ drug to fall over the 'patent cliff' - cholesterol-lowerer Crestor (rosuvastatin) - saw sales cut in half in the fourth quarter after the loss of US patent protection, with

AZ slims down again with sale of antibiotics to Pfizer

up cash flow in the face of a looming patent expiry for Crestor (rosuvastatin) in the US.

AZ feels Crestor sting but new products provide some relief

AstraZeneca saw second quarter revenues and profits slide as competition to cholesterol drug Crestor took hold in the US. ... Overall, revenues fell 10% to $5.6bn in the second quarter, with Crestor (rosuvastatin) slipping 29% to $926m following the

AZ sells Zurampic rights to Gruenenthal for $230m

light of the loss of patent protection for blockbuster brands such as cholesterol drug Crestor (rosuvastatin) and Nexium (esomeprazole) for gastrointestinal diseases.

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]